A PHASE 3, MATRIX DESIGN, PARTIALLY DOUBLE-BLIND, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF 50 MG LONAFARNIB / 100 MG RITONAVIR BID WITH AND WITHOUT 180 MCG PEG IFN-ALFA-2A FOR 48 WEEKS COMPARED WITH PEG IFN-ALFA-2A MONOTHERAPY AND PLACEBO TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HEPATITIS DELTA VIRUS BEING MAINTAINED ON ANTI-HBV NUCLEOS(T)IDE THERAPY (D-LIVR)

Registry ID

EIG-LNF-011

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

EIGER BIOPHARMACEUTICALS, INC

Start date

2020-06-26

Completion date

2022-12-28

Last update

2019-03-01

Conditions

• HEPATITIS D

Related clinical trials

• A GLOBAL, RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 2B/3 TRIAL EVALUATING BJT-778 VS DELAYED TREATMENT FOR THE TREATMENT OF CHRONIC HEPATITIS DELTA INFECTION (AZURE-1)
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOBEVIBART+ELEBSIRAN COMBINATION THERAPY IN PARTICIPANTS WITH CHRONIC HDV INFECTION (ECLIPSE 1)

View on source registry